| January 30, 2012 |
| January 15, 2013 |
| January 2012 |
| December 2013 (final data collection date for primary outcome measure) |
| The Increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0). [ Time Frame: baseline and 24 hours after induction of ischemia ] [ Designated as safety issue: No ] |
| Same as current |
| Complete list of historical versions of study NCT01534364 on ClinicalTrials.gov Archive Site |
- Urine Neutrophil-Gelatinase associated Lipocalin (NGAL in µg/l) 8h after induction of ischemia in comparison to baseline value obtained in the morning of the day of surgery (day 0). [ Time Frame: baseline and 8 hours after induction of ischemia ] [ Designated as safety issue: No ]
- C-reactive Protein (CRP) 24h after induction of ischemia [ Time Frame: baseline and 24 h after induction of ischemia ] [ Designated as safety issue: No ]
- Leucocyte count 24h after induction of ischemia [ Time Frame: baseline and 24h after induction of ischemia ] [ Designated as safety issue: No ]
- Creatinkinase (CK) 24h after induction of ischemia [ Time Frame: baseline and 24 h after induction of ischemia ] [ Designated as safety issue: No ]
- Troponin T 24h after induction of ischemia [ Time Frame: baseline and 24 h after induction of ischemia ] [ Designated as safety issue: No ]
- Lactate dehydrogenase 24h after induction of ischemia [ Time Frame: baseline and 24 h after ischemia ] [ Designated as safety issue: No ]
- N-terminal pro brain natriuretic peptide (NT-ProBNP) 24h after induction of ischemia [ Time Frame: baseline and 24 h after ischemia ] [ Designated as safety issue: No ]
- Serum lactate 24h after induction of ischemia [ Time Frame: baseline and 24 hours after ischemia ] [ Designated as safety issue: No ]
- Maximum increase of serum creatinine within the first 48 h after induction of ischemia [ Time Frame: baseline and 48 hours after ischemia ] [ Designated as safety issue: No ]
- Necessity of renal replacement therapy during hospital stay [ Time Frame: pt will be followed for the duration of hospital stay, an expected average of 10 days ] [ Designated as safety issue: No ]
- In-hospital mortality [ Time Frame: pt will be followed for the duration of hospital stay, an expected average of 10 days ] [ Designated as safety issue: No ]
- Time until fit for discharge [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days ] [ Designated as safety issue: No ]
- Length of hospital stay [ Time Frame: Pt will be followed for the duration of hospital stay an expected average of 10 days ] [ Designated as safety issue: No ]
- Echocardiographic estimated left-ventricular ejection fraction as per file, if assessed postoperatively [ Time Frame: baseline and postoperatively, expected within 10 days after operation ] [ Designated as safety issue: No ]
- Occurrence of acute renal failure in accordance with KDIGO I, II, III [ Time Frame: Patients will be followed during hospital stay, an expected average of 10 days ] [ Designated as safety issue: No ]
|
- Urine Neutrophil-Gelatinase associated Lipocalin (NGAL in µg/l) 8h after induction of ischemia in comparison to baseline value obtained in the morning of the day of surgery (day 0). [ Time Frame: baseline and 8 hours after induction of ischemia ] [ Designated as safety issue: No ]
- C-reactive Protein (CRP) 24h after induction of ischemia [ Time Frame: baseline and 24 h after induction of ischemia ] [ Designated as safety issue: No ]
- Leucocyte count 24h after induction of ischemia [ Time Frame: baseline and 24h ] [ Designated as safety issue: No ]
- Creatinkinase (CK) 24h after induction of ischemia [ Time Frame: baseline and 24 h after induction of ischemia ] [ Designated as safety issue: No ]
- Troponin T 24h after induction of ischemia [ Time Frame: baseline and 24 h after induction of ischemia ] [ Designated as safety issue: No ]
- Lactatedehydrogenase 24h after induction of ischemia [ Time Frame: baseline and 24 h after ischemia ] [ Designated as safety issue: No ]
- N-terminal pro brain natriuretic peptide (NT-ProBNP) 24h after induction of ischemia [ Time Frame: baseline and 24 h after ischemia ] [ Designated as safety issue: No ]
- Serum lactate 24h after induction of ischemia [ Time Frame: baseline and 24 hours after ischemia ] [ Designated as safety issue: No ]
- Maximum increase of serum creatinine within the first 48 h after induction of ischemia [ Time Frame: baseline and 48 hours after ischemia ] [ Designated as safety issue: No ]
- Necessity of renal replacement therapy during hospital stay [ Time Frame: pt will be followed for the duration of hospital stay, and expected time of 10 days ] [ Designated as safety issue: No ]
- In-hospital mortality [ Time Frame: pt will be followed for the duration of hospital stay, an expected time of 10 days ] [ Designated as safety issue: No ]
- Time until fit for discharge [ Time Frame: time until fit for discharge, an expected average time of 10 days ] [ Designated as safety issue: No ]
- Length of hospital stay [ Time Frame: Pt will be followed for the duration of hospital stay an expected time of 10 days ] [ Designated as safety issue: No ]
- Echocardiographic estimated left-ventricular ejection fraction as per file, if assessed postoperatively [ Time Frame: baseline and postoperatively, expected within 10 days after operation ] [ Designated as safety issue: No ]
- Occurrence of acute renal failure in accordance with KDIGO I, II, III [ Time Frame: Patients will be followed during hospital stay, an expected time of 10 days ] [ Designated as safety issue: No ]
|
| Not Provided |
| Not Provided |
| |
| Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery |
| Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery |
The aim of this study is to assess the effect of a diet prior to cardiac surgery on the common postoperative decline of renal function. Until now, there is no known drug or procedure to preserve the kidneys from this impairment. Patients with a known kidney disease are especially at risk. A potential beneficial effect of a diet prior to surgery has been shown in investigations in mammals, therefore this study will investigate if a preoperative diet in patients with known kidney disease and scheduled heart surgery can attenuate or prevent a postoperative loss of kidney function. |
Patients with cardiothoracic surgery are at risk for postoperative acute renal failure which is associated with significant morbidity and mortality. There is no drug or procedure known to prevent this loss of renal function. Experimental data suggests, that a preoperative caloric restriction might provide kidney protection in this context. This clinical trial investigates if this phenomenon is also applicable in humans. Patients with a increased risk for a postoperative renal failure due to known chronic kidney disease are randomized in 2 groups. Patients of the diet group receive a calorie restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery). Patients of the control group receive alimentation ad libitum.
Primary objective is the increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0) in order to analyse if a preoperative calorie restriction as a preventive strategy leads to a attenuation of postoperative kidney injury. Hypothesis: A seven day calorie restriction reduces the increase of serum creatinine after cardiac surgery in patients with known chronic kidney disease. |
| Interventional |
| Not Provided |
Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Acute Renal Failure |
| Other: calorie restriction
Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
Other Name: calorie restriction with Fresubin energy fibre drink |
|
|
| Not Provided |
| |
| Recruiting |
| 82 |
| June 2014 |
| December 2013 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Men and women 18 years of age or older
- Caucasian origin
- Scheduled cardiothoracic operation with employment of cardio-pulmonary bypass and a lead time of 11 days minimum.
- Indication for cardiac surgery is determined by the cardiothoracic specialist
- Patient and/or legal guardian must be willing and able to give written informed consent
one of the following risk factors:
- serum creatinine > 0,9 mg/dl in female
- type 2 diabetes
- peripheral artery occlusive disease
- heart failure (ejection fraction < 50 %)
- combined CABG and heart valve surgery
- further surgery after CABG or heart valve surgery
Exclusion Criteria:
- End-stage renal disease (patient on dialysis)
- Indwelling kidney transplant
- Malnutrition (BMI < 18,5 kg/m2)
- Body weight < 46 kg in male < 51 kg in female
- BMI > 35 kg/m2 or body weight > 120 kg
- Catabolic state (serum albumine < 25 g/l)
- Diet within the previous 4 weeks
- Inappetence
- Weight loss > 1 kg within the previous 2 weeks, if not explained by use of diuretics
- Hospital stay during the last 7 days prior to cardiac surgery
- Consuming underlying disease
- Uncontrolled local or systemic infection
- Contraindication for enteral nutrition.
- Known allergy against or incompatibility with ingredients of the employed formula-diet
- Pregnancy or breast feeding
- Participation in other interventional clinical trials.
- Missing safe method of contraception or missing occurence of menopause (in female)
- Professional or private relationship between subject and the investigators or dependence on the investigators.
- Placement in an institution based on official orders.
|
| Both |
| 18 Years and older |
| No |
|
|
| Germany |
| |
| NCT01534364 |
| 001, 00003355 |
| Yes |
| Volker Burst, University of Cologne |
| University of Cologne |
| Fresenius Kabi |
| Principal Investigator: |
Volker Burst, MD |
University of Cologne |
|
|
| University of Cologne |
| January 2013 |